<DOC>
	<DOC>NCT00044694</DOC>
	<brief_summary>This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months prior to screening. Patients whose diabetes management consists of diet and exercise will also be eligible for this study.</brief_summary>
	<brief_title>Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subjects with type 2 diabetes Treated with diet and exercise alone or with metformin for at least 3 months prior to screening BMI 2745 kg/m^2 HbA1c between 7.0 % and 8.0 % Treated with other oral antidiabetic agents other than metformin within 3 months of screening Patients previously treated with AC2993 Patients presently treated with insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
</DOC>